Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga
Author: Neamati, Nouri
Source: Expert Opinion on Therapeutic Patents, Volume 12, Number 5, 1 May 2002 , pp. 709-724(16)
Publisher: Informa Healthcare
Validation of integrase as a suitable therapeutic target for the development of drugs against HIV infection; discovery of diketo acid derivatives as bona fide inhibitors of integrase and the recent news of Phase II clinical trials with S-1360 are major findings fuelling the recent surge of interest in the development of integrase inhibitors. Herein, the first review of the entire patent literature for small molecule intergrase inhibitors is presented. The emphasis is based on compounds with potential to serve as leads, therefore, no attempts are made to include: antibodies, oligonucleotides or polypeptides.
Document Type: Miscellaneous
Affiliations: University of Southern California, School of Pharmacy, Department of Pharmaceutical Sciences, 1985 Zonal Avenue, PSC 304BA, Los Angeles, CA 90089, USA, Tel: +1 323 442 2341, Fax: +1 323 442 1390, Email: firstname.lastname@example.org
Publication date: 1 May 2002